Stockbroker · United States

Lucid Capital Markets

Deals
10
M&A
6
Equity raisings
4
Latest
Jul 2026
Compare

Deals

Deals dated after 30 September 2026 are still being collected.

Columns
Deal size
Custom range

10 of 10 deals

Deals Lucid Capital Markets advised on, most recent first
Advisers
Jul 2026 Synlogic ––MergerFinancial adviser to Synlogic (target)Announced–Biotech+1 Mintz (sell-side)Fenwick & West (buy-side) Caldera Therapeutics and Synlogic merger
Jun 2026 SharonAI Holdings ––PlacementPlacement agent to the lead managersCompleted1,600.0AI Infrastructure+2 Goldman Sachs (lead manager)Macquarie Capital (issuer)Sheppard, Mullin, Richter & Hampton (issuer) SharonAI Holdings placement
Jun 2026 Serapha Bio –Boundless BioMergerFinancial adviser to Boundless Bio (acquirer)Pending–Biotech+1 Latham & Watkins (buy-side)Wedbush Securities (sell-side)Gibson Dunn (sell-side)Goodwin (sell-side) Boundless Bio and Serapha Bio merger
Jun 2026 Azora Therapeutics –Adial PharmaceuticalsAsset saleFinancial adviser to Azora (target)Completed–Biotech+2 Oppenheimer & Co. (buy-side)Blank Rome (buy-side)Honigman (sell-side) Adial Pharmaceuticals acquisition of Azora Therapeutics
Jun 2026 Adial Pharmaceuticals ––PlacementPlacement agent to the lead managersPending32.0Biotech+1 TD Securities (issuer) Adial Pharmaceuticals placement
May 2026 Mentari Therapeutics –InMed PharmaceuticalsAcquisitionFinancial adviser to InMed Pharmaceuticals (acquirer)Announced–Biotech+1 Norton Rose Fulbright (buy-side)Wedbush Securities (sell-side)Gibson Dunn (sell-side) InMed Pharmaceuticals acquisition of Mentari Therapeutics
May 2026 Exyn Technologies ––IPOUnderwriterAnnounced19.4Robotics+2 DLA Piper (issuer)Loeb & Loeb (lead manager) Exyn Technologies IPO
Apr 2026 Obsidian Therapeutics –Galera TherapeuticsMergerFinancial adviser to Galera Therapeutics (acquirer); Fairness opinion to Galera’s Board of Directors (acquirer)Completed413.5Biotech+2 Sidley Austin (buy-side)Goodwin (sell-side)Leerink Partners (sell-side) Galera Therapeutics and Obsidian Therapeutics merger
Mar 2026 Swarmer ––IPOBookrunnerAnnounced15.0Defence & Aerospace+1 Mintz (issuer)Ellenoff Grossman & Schole (lead manager) Swarmer IPO
Feb 2026 Faeth Therapeutics –Sensei BiotherapeuticsAcquisitionFinancial adviser to Sensei Biotherapeutics (acquirer)Completed–Biotech+2 Sidley Austin (buy-side)Cooley (sell-side) Sensei Biotherapeutics acquisition of Faeth Therapeutics

Activity

Deals by year
Lucid Capital Markets: deals by year2025: 0, 2026 YTD: 10051020252026 YTD: 6 M&A2026 YTD: 4 Equity raisings102026 YTDM&AEquity raisings

By announcement date; raisings and IPOs by their own date.

Deals by sector
Lucid Capital Markets: deals by sectorBiotech7AI1Defence & Aerospace1Robotics1

Sector of the business bought or funded.

Deals by size
Lucid Capital Markets: deals by sizeUnder US$100m3US$100–500m1US$1bn+1Undisclosed5

Disclosed value in US dollars.

Most often across the table

Firms advising the other side of the same deals.

Offices and contact

Contact

From the firm's own website.

Suggest a correction

A missing deal, a wrong role or an office to add. A link to a public source helps.